Navigation Links
QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy

Efficacy and Safety Study to Support Phase 3 Combination Rule Trial for NDA Submission

SYDNEY, Australia and BEDMINSTER, N.J., Dec. 15 /PRNewswire-FirstCall/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapies for pain and central nervous system (CNS) disorders, announced today initiation of a comparative study to evaluate the efficacy and safety profile of MoxDuoIR(TM) against equivalent analgesic doses of morphine and oxycodone alone for the treatment of acute moderate to severe pain. Data collected from this study will also be used to support final Phase 3 trials required for NDA submission. The Company expects to complete dosing prior to Q2 2009.

"While successful clinical trials to date have shown the potential of MoxDuo(TM) to provide equal or better analgesia with a reduction of total opioid dose and improved tolerability, this study is designed to provide direct evidence of enhanced efficacy when compared to equivalent analgesic doses of morphine and oxycodone alone," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "Our goal is to demonstrate the clinical value and superiority of MoxDuoIR(TM) over its individual components in post-surgical acute pain relief."

The double-blind, randomized and repeated fixed-dose study compares MoxDuoIR's(TM) efficacy and safety to corresponding doses of oxycodone and morphine in patients experiencing moderate to severe pain following a scheduled surgical procedure (bunionectomy). The study is targeted to enroll 180 patients at 6 US clinical research sites.

The primary clinical endpoints for this study focus on pain relief and intensity scores of MoxDuoIR(TM) versus equivalent doses of morphine and oxycodone alone during the first 24 hours following surgery. Secondary endpoints include: (1) efficacy relating to the time to onset of analgesia and global assessment of effect; and (2) safety as measured by the incidence and intensity of opioid-related adverse events.

MoxDuoIR(TM) is a patented combination of morphine and oxycodone which has been clinically shown to provide synergistic effects on pain relief, resulting in a significant reduction of total opioid dose and side effects.

Based on the Company's July 2008 FDA meeting, final Phase 3 studies for MoxDuoIR(TM) will include a combination rule trial in patients experiencing post-surgery (bunionectomy) pain. Data collected from the comparative study will be used to select the optimal dose regimen and sample sizes for the combination rule trial. No additional pharmacology, toxicology or long-term clinical safety studies will be required for regulatory submission and market approval.

Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of QRxPharma as of the date of this release. These forward-looking statements are not guarantees for future performance. Actual results could differ materially from those currently anticipated to due to a number of factors including risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization of the Company's proposed products.

About QRxPharma

QRxPharma (ASX: QRX) is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy which focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. The Company intends to directly commercialize its products in the US and seek strategic partnerships abroad. QRxPharma's lead compound, MoxDuoIR(TM), successfully completed a Phase 3 study and met primary and secondary endpoints. The Company's preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics. For more information:

SOURCE QRxPharma Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
2. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
3. Trinity Biotech Investor Group Initiates Campaign of ADR Conversion to Force a Special Meeting of Shareholders
4. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
5. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
6. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
7. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
8. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
11. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
Post Your Comments:
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/25/2015)... 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... a fireside chat discussion at the Piper Jaffray 27th ... . The discussion is scheduled for Wednesday, December 2, ... .  A replay will be available for 14 days ... , Julie NormartVP, Corporate Communications and Business Development , ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... ... 24, 2015 , ... The United States Golf Association (USGA) today announced Dr. ... Award. Presented annually since 1961, the USGA Green Section Award recognizes an individual’s distinguished ... , Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology in ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... High Tech Association (MHTA) as one of only three ... the "Software – Small and Growing" category. The Tekne Awards ... who have shown superior technology innovation and leadership. ...
(Date:10/29/2015)... 2015  Connected health pioneer, Joseph C. Kvedar ... technology-enabled health and wellness, and the business opportunities that ... The Internet of Healthy Things . Long before ... existed, Dr. Kvedar, vice president, Connected Health, Partners HealthCare, ... moving care from the hospital or doctor,s office into ...
(Date:10/27/2015)... October 27, 2015 Munich, ... Gaze Mapping technology (ASGM) automatically maps data from mobile ... Glasses , so that they can be quantitatively ... Munich, Germany , October 28-29, 2015. ... data from mobile eye tracking videos created with ...
Breaking Biology News(10 mins):